Related Experiment Video
Updated: Apr 10, 2026
05:19
Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
Published on: March 29, 2019
11.0K
Cyclooxygenase-2 polymorphisms and bladder cancer risk: a meta-analysis based on case-control studies
Guo-Xing Wan1, Ping Chen1, Xiong-Jie Yu1
1Department of Oncology, Renmin Hospital, Hubei University of Medicine Shiyan 442000, Hubei, China.
Summary
This meta-analysis found that Cyclooxygenase-2 (Cox-2) gene polymorphisms rs5275 and rs20417 are associated with bladder cancer risk, particularly in Chinese and American populations. The rs689466 polymorphism showed a decreased risk in Indian populations.
Area of Science:
- Genetics and Epidemiology
- Cancer Research
Background:
- Bladder cancer is a significant global health concern.
- Genetic factors, including polymorphisms in the Cyclooxygenase-2 (Cox-2) gene, are implicated in bladder cancer susceptibility.
- Understanding these genetic associations can inform risk assessment and prevention strategies.
Purpose of the Study:
- To conduct a meta-analysis to precisely estimate the association between three common Cox-2 gene polymorphisms (rs20417, rs689466, and rs5275) and bladder cancer risk.
- To investigate potential ethnic variations in these associations.
Main Methods:
- A systematic search of electronic databases was performed to identify relevant case-control studies.
- The meta-analysis included 15 case-control studies with 4,138 cases and 4,269 controls.
- Statistical analyses were conducted to calculate odds ratios (ORs) and confidence intervals for different genotypes and alleles.
Main Results:
- The rs5275 polymorphism was significantly associated with bladder cancer risk, particularly in Chinese and American populations.
- The rs20417 polymorphism showed varied associations: increased risk in Chinese and Indian populations, but a reduced risk in Americans.
- The rs689466 polymorphism was associated with a decreased risk of bladder cancer in the Indian population.
Conclusions:
- Cox-2 rs5275 polymorphism is a potential contributor to bladder cancer risk, especially in Chinese and American individuals.
- Cox-2 rs20417 polymorphism exhibits differential effects across ethnicities, acting protectively in some and as a risk factor in others.
- Cox-2 rs689466 polymorphism appears to be associated with a reduced risk of bladder cancer in Indian populations, suggesting ethnic-specific genetic influences on bladder cancer development.
More Related Videos
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
213
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
213
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
122
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
122
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
74
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
74
01:05Single Nucleotide Polymorphisms-SNPs
20.0K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
20.0K
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
147
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
147